Advertisement
Organisation › Details
Kadans Science Partner (NL)
Originally founded in the late 1990s, Kadans evolved its focus on developing and operating specialised or purpose-built commercial life science buildings. Kadans’ assets combine offices and incubator space alongside a range of specialist spaces including laboratories and cleanrooms and tech halls, as well as research and development facilities such as climate controlled environments and pilot plants. Kadans’ tenant base comprises a mix of, global corporate, SME and start-up businesses, as well as academic and government institutions in highly innovative growth sectors such as Life Sciences, Food, Health, Living Environment, Biotechnology, Bio based and High Tech Semiconductors. A key element of Kadans’ success has been the creation of innovation ecosystems not just within the individual building and campuses it operates in, but across its whole network of tenants and relationships across Europe. By promoting networking, connectivity and events management for tenants, public bodies and academic institutions, Kadans is able to help enhance information flow and knowledge sharing. *
Start | 2020-12-01 existent | |
Group | Axa (Group) | |
Industry | real estate | |
Industry 2 | business park management / science park management | |
Region | Netherlands_oo | |
Country | Netherlands | |
Street | 5 Rijksweg | |
City | 5076 PB Haaren | |
Tel | +31-411-625625 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: AXA Investment Managers. (7/26/21). "Press Release: AXA IM Alts Raises €1.9 Billion for European Life Sciences Investments". | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Axa (Group)
- [1] Kadans Science Partner. (1/29/24). "Press Release: Kadans Becomes New Partner for Rheinland-Pfalz Location – Collaboration with Technologiezentrum Mainz"....
- [2] BioInvent International AB. (7/12/22). "Press Release: BioInvent Has Successfully Carried Out a Directed Share Issue of approximately SEK 300 Million (approximately USD 28.3 Million) [ Not for US, AU, et al. ]". Lund....
- [3] AXA Investment Managers. (4/4/22). "Press Release: AXA IM Alts Launches $500 Million Private Equity Healthcare Strategy alongside Two Senior Appointments"....
- [4] Kadans Science Partner. (3/30/22). "Press Release: Europe’s Largest Commercial Lab Building to Be Built at Canary Wharf, London"....
- [5] AXA Investment Managers. (7/26/21). "Press Release: AXA IM Alts Raises €1.9 Billion for European Life Sciences Investments"....
- [6] AXA Investment Managers. (11/26/20). "Press Release: AXA Investment Managers - Real Assets to Enter European Life Science Sector with Acquisition of Kadans Science Partner Platform"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top